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SUMMARY 
The purpose of our study was to investigate the prognostic value of clinical and pathological, in 
particular glomerular and tubulointerstitial morphometric variables in idiopathic membranous 
nephropathy. We prospectively followed 60 Caucasian patients diagnosed with idiopathic 
membranous nephropathy for at least 2 years or until primary outcome (>=50% permanent 
decrease in estimated glomerular filtration rate or death). Glomerular and tubulointerstitial 
morphometric variables at the time of renal biopsy were analyzed with respect to this outcome. 
Univariate analysis revealed that significant negative prognostic factors for this outcome were 
higher cholesterol and smaller albumin concentrations, higher creatinine and maximal 24-hour 
proteinuria, higher grade of nephroangiosclerosis, higher glomerular basement membrane 
thickness and glomerulopathy index, higher interstitial fibrosis and tubular atrophy percentage 
and higher injury score. In multivariate analysis, only the maximal 24-hour proteinuria and  
interstitial fibrosis and tubular atrophy percentage were independent predictors of this outcome. 
The results suggest that morphometric analysis, mainly quantitative measurement of interstitial 
fibrosis and tubular atrophy percentage, injury score, glomerular basement membrane thickness 
and glomerulopathy index could be used as an additional method for risk stratification of patients 
with idiopathic membranous nephropathy. 
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INTRODUCTION 
Idiopathic membranous nephropathy (IMN) is one of the most common primary 
glomerulonephritides, accounting for 9.7% to 29.4% [3, 9, 17]. It is considered the most common 
cause of nephrotic syndrome in adults [22, 25]. It has a very variable clinical course with all 
possible outcomes, ranging from spontaneous remission, with a reported incidence between 32 
and 67%, to progressive deterioration and development of end-stage renal disease (ESRD), with 
a reported incidence between 12 and 44% [7, 18, 21, 26]. Considering a variable clinical course, 
identification of specific and sensitive prognostic factors is of great importance for the selection 
of patients undergoing immunosuppressive treatment. Numerous prognostic factors have been 
validated in IMN, and for most of them, low specificity and/or sensitivity was found [4, 7, 12, 
16, 20, 22, 25, 27]. Glomerular and tubulointerstitial morphometric analysis is being used as a 
complementary method of routine analysis of renal biopsy in various diseases [23]. Regarding 
IMN, only a few studies used morphometric analysis [1, 19, 24]. The aim of this study was to 
validate glomerular and tubulointerstitial morphometric prognostic factors, as well as clinical 
factors, in our cohort of patients with IMN. 
 
MATERIAL AND METHODS 
We included patients having undergone kidney biopsy in two Nephrology Departments in 
Zagreb, Croatia, between 1996 and 2009, and diagnosed with IMN. Patients with secondary 
forms of membranous nephropathy were excluded from the study. Age, gender, arterial blood 
pressure, serum creatinine, estimated glomerular filtration rate (EGFR), calculated according to 
the CKD-EPI formula [14], serum cholesterol, albumin and maximal 24-hour proteinuria (until 
the biopsy) were recorded at the time of biopsy. In all patients, kidney biopsy was performed, 
and all specimens were processed for light, immunofluorescence and electron microscopy using 
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standardized techniques. The histopathological parameters analyzed were as follows: Ehrenreich 
and Churg disease stage I to IV [6], semiquantitatively defined nephroangiosclerosis grade (0-
none, 1-mild, 2-moderate, 3-severe), immunoglobulin G deposition grade (0-lack of deposition, 
1-mild, 2-moderate, 3-severe), complement C3 deposition grade (0-lack of deposition, 1-mild, 2-
moderate, 3-severe), presence of secondary focal segmental glomerulosclerosis (FSGS) and 
heterogenicity of immune deposits (synchronous electron dense deposits with a single stage in all 
analyzed glomeruli were arbitrarily classified as homogenous type and others having various 
stages as heterogeneous type, according to Yoshimoto et al.) [30]. Morphometric analysis was 
carried out by a semiautomatic image analysis procedure, using the optical microscope Olympus 
BX41 with camera Olympus DP71 connected with PC and with ImageJ image analysis software 
(http://rsb.info.nih.gov/ij/). Glomerular morphometry was carried out by analysis of light 
microscopy (PAS-stained images with a magnification of x400). In each case, 5-10 glomeruli, 
cut through hilum or having complete outline of Bowman's capsule, were selected for glomerular 
morphometry. Biopsies with less than 5 glomeruli were not included in the study. After opening 
the image, ImageJ measurement tools were calibrated by micrometer specific to the 
magnification into standard units (mm, µm and nm). Glomerular morphometric parameters 
measured were: glomerular diameter (GD), tuft diameter (TD), glomerular area (GA), tuft area 
(TA), mesangial matrix and membranes area (MA), urinary space area (UA=GA-TA), capillary 
space area (CA=TA-MA), tuft volume fraction (TVF=(TA/GA)x100), urinary space volume 
fraction (UVF=(UA/GA)x100), membranes and mesangial matrix volume fraction 
(MVF=(MA/GA)x100) and capillary space volume fraction (CVF=(CA/GA)x100), as described 
earlier by Rayath et al. [24]. After obtaining color image by Image/Color/Split channels tool, red, 
green and blue channels of the image were separated, and for further analysis, the green channel 
was kept, because it gives the sharpest glomerular image. Using a free-hand tool from the menu 
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bar and tracing the outline of the glomerulus and then the tuft, an area was selected as region of 
interest (ROI), and then, using Analyze/Measure tool, GA, TA and MA measured. MA was 
measured by Image/Type/8-bit tool to convert the green channel of the original image to 
grayscale, and then the threshold for staining detection was set by selecting 
Image/Adjust/Threshold tool. The final grayscale image was created in which black areas 
approximately represent mesangial matrix and membrane areas (MA), as reported earlier by 
Rayath et al. [24]. For every glomerular morphometric parameter measured, the mean of all 
values measured in a single biopsy was used as reference value for the individual patient. 
Morphometric measurement of interstitial fibrosis and tubular atrophy (IFTA) was carried out by 
analyzing Masson-trichrome stained images with a magnification of x400 (areas of fibrosis are 
stained blue). After separating the glomerules and medulla from the cortex, blue color was 
defined as ROI by selecting one blue area with a freehand tool and then by clicking the 
Image/Adjust/Color threshold tool and Sample button, which removed pixels not falling into the 
selected color range. After that, the image is converted into binary (8-bit), and the whole biopsy 
cylinder is marked as ROI. Then, using Analyze Particles tool, the Area fraction was determined 
which represents IFTA (in percentage) (described earlier in detail by Rangan and Tesch) [23]. 
Injury score (IS) is a marker of chronic damage and has recently been shown to have prognostic 
value in focal segmental glomerulosclerosis [29]. It is calculated as IS = (number of segmental 
sclerotized glomeruli + number of globally sclerotized glomeruli)/total number of glomeruli + 
IFTA (expressed as an absolute number). Electron microscopy was carried out using JEOL JEM-
1400 electron microscope. Glomerular basement membrane thickness (GBMT) was ascertained 
on images at a magnification x8000. GBMT was determined as a harmonic mean of 100 
orthogonal intercepts across the glomerular basement membrane (GBM) measured from at least 
5 glomerular capillary loops by line tool of ImageJ software on the acquired images after 
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calibration for magnification. Harmonic mean was multiplied by 8/3π to correct the measuring 
error due to oblique sectioning of capillary walls [13, 24]. In each measurement, GBMT was 
defined as a distance between endothelial cell and podocyte membrane, and included 
intramembranous immune deposits. Glomerulopathy index (GPI) was calculated by the formula 
GPI=1/10xGBMT+MVF (according to Rayat et al.) [24]. 
Follow-up started at the time of biopsy. It was minimally 2 years and continued until February 
2011 or until the primary outcome. Serum creatinine and 24-hour proteinuria were measured 
every 3 months during follow-up, and EGFR was calculated. Combined primary outcome was 
renal failure (RF, defined as >=50% permanent decrease in EGFR from baseline values) or 
death.  
Statistical analysis was performed using the SPSS version 17.0 for Windows and MedCalc 
version 12.2. Normally distributed variables were expressed as mean±standard deviation and 
compared using Student's t-test. Nonparametric continuous variables were expressed as median 
and interquartile range and compared using Mann-Whitney U test. Categorical variables were 
expressed in percentage and compared using χ
2
-test or Fischer’s exact test. Univariate 
comparisons for outcomes were performed by Kaplan-Meier curves and log-rank test. Receiver 
operating characteristics (ROC) curves analysis was made to determine area under curve (AUC) 
and to calculate the sensitivity and specificity of various clinical and morphometric baseline 
variables in the prediction of primary outcome, using the most discriminative thresholds (cut-off 
values). A multivariate Cox proportional hazard model was constructed to determine 
independent variables associated with primary outcome. Only variables associated by univariate 
analysis were included in a multivariate model. For all analyses, p<0.05 was considered 
significant. 
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RESULTS 
Sixty Caucasian patients were included in this study. Nephrotic syndrome was present in 93.3% 
of the patients. Tables 1, 2 and 3 show the baseline clinical, histological and morphometric 
parameters with respect to primary outcome. The patients were treated nonrandomly, following 
guidelines [2, 5, 8, 22]; 85% of the patients with immunosuppressives (56.7% with 
glucocorticoid + alkylating agent, 18.3% with glucocorticoid+cyclosporin and 10% with 
glucocorticoid alone), and 90% of the patients received renin-angiotensin inhibiting drugs. 
Patients were followed for a median of 48 months (range 6 to 132 months). During follow-up, 12 
patients reached primary outcome (20%), two patients died (one of thromboembolic incident; for 
the other one, the cause of death was unknown). The estimated probability of survival without 
primary outcome was 79.0±6.8% at 60 months and 62.7±10.0% at 84 months (Kaplan-Meier 
survival analysis). In univariate analysis, higher serum creatinine (lower EGFR), higher serum 
cholesterol and lower albumin concentration were associated with primary outcome. 
Pathohistological and morphometric variables associated with primary outcome were higher 
nephroangiosclerosis grade, higher GBMT and GPI, higher IFTA percentage and higher IS. 
Other morphometric and pathohistological variables tested were not associated with primary 
outcome. The ROC analysis showed that the most discriminative variables in the prediction of 
primary outcome were IFTA and IS (Table 4). The optimal cut-off value of IFTA was 18%, and 
that of IS 0.322 (Figs. 1 and 2). Kaplan-Meier survival analysis showed that renal and patient 
survival (primary outcome) was significantly higher in patients with IFTA<=18% (Fig. 3) and  
IS<=0.322 (Fig. 4). Cox proportional hazards model included variables selected by univariate 
analysis. The results are shown in Table 5. The only independent predictors of primary outcome 
were maximal 24-hour proteinuria (hazard ratio, HR=1.127) and IFTA (HR=1.029). We also 
created a similar Cox proportional hazards model with IFTA as a categorical variable, using cut-
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off values on the basis of ROC analysis and AUC. The newe model remained statistically stable 
also, showing that patients with IFTA>18% had HR=17.662 for primary outcome (95% 
confidence interval 2.235-139.581; p=0.006) compared to patients with IFTA<=18%. Because 
our study may be biased due to nonrandomized immunosuppressive therapy, we additionally 
performed the ROC analysis, including only patients given immunosuppressive therapy, and the 
results for IFTA and IS were similar (cut-off for IFTA>18%, AUC=0.854, sensitivity 90.0%, 
specificity 75.61%, p<0.0001).  
 
DISCUSSION 
There are numerous studies with a focus on prognostic factors in IMN, but their results 
vary considerably. The reason for this is most probably due to a great variation in inclusion 
criteria and in the outcomes evaluated, as stipulated by Marx et al. [15]. Consequently, there is a 
large diversity in the results of the prognostic factors studied, so that for virtually every 
prognostic factor investigated, there are studies demonstrating or refuting its significance in IMN 
[15, 25]. This study attempted to overcome some shortcomings of previous studies by focusing 
on glomerular and tubulointerstitial morphometric variables in a well-defined cohort of patients 
with IMN. Our outcome was defined as proposed by Marx et al. [15].  
It is interesting that in our study, gender and age were not found to be statistically 
significant predictors of RF. This corroborates the findings of most recent studies in which age 
and male gender were not significant predictors of outcome as well [28, 30]. In the majority of 
studies, as well as in ours, hypertension was not found to be an independent predictor of RF [22, 
25]. Only Heeringa et al. [10] reported that diastolic blood pressure is an unfavorable predictor 
for RF (but defined as serum creatinine >135µmol/l). The prognostic significance of renal 
function (measured by serum creatinine and/or EGFR) at the time of diagnosis is potentially 
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biased because of a transitory decrease in GFR in patients with severe nephrotic syndrome, and 
because of the fact that a shorter renal survival time in patients with permanently decreased 
baseline renal function may result from baseline chronic kidney injury that may not be a 
consequence of the IMN itself, as shown by Troyanov et al. [28]. In line with that, we found 
renal function to be associated with primary outcome only in univariate, but not in multivariate 
analysis. Similar results were published by Marx et al. [16] and Yoshimoto et al. [30], while 
Heeringa et al. [10] reported serum creatinine as an independent predictor. We found baseline 
24-hour proteinuria as an unfavorable predictor for RF in univariate analysis and multivariate 
analysis, which is consistent with other studies [11, 16, 30].  
The main focus of our study was the evaluation of morphometric variables in the 
prognosis of IMN. We found IFTA, measured quantitatively, as a significant predictor for renal 
and patient survival in both univariate and multivariate analysis. In the present study, some other 
histological indices (GBMT, GPI and IS) were significantly associated with progression of renal 
dysfunction only in univariate analysis, while morphometric variables related to glomerular size 
and volume fractions, as well as immunoglobulin and complement deposition grade and FSGS, 
were not found to be predictive of RF.  A predictive value of quantitatively measured IFTA 
demonstrating that even low grade of IFTA (IFTA>18%) was associated with a significantly 
worse renal outcome, independent of immunosuppressive therapy, is the major finding of our 
study. We believe that this does not implicate that patients with IFTA>18% should not be treated 
with immunosuppressives, but it rather reflects possible additional non-immunological 
mechanisms of disease progression. It is important to recall that in the present study, virtually all 
patients were treated with angiotensin-blocking drugs. Thus, additional possible mechanisms of 
IMN progression, besides inflammation and the renin-angiotensin pathway, should be the target 
of future studies. Follow-up renal biopsies may be one of the tools for studying mechanisms of 
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the disease progression, as well as the effect of established drugs and potential new drugs. In 
most recent studies, IFTA was found to be an unfavorable prognostic factor for the outcomes of 
ESRD and RF only in univariate analysis [10, 16, 28, 30]. In multivariate analysis, IFTA was 
found to be a negative predictive factor only in the studies by Yoshimoto et al. [30] and 
Paraskevakou et al. [19]. It is important to note that in the latter study, IFTA was measured 
quantitatively as well. In the study conducted by Yoshimoto et al. [30], only a relatively small 
percentage of patients were treated by the standard immunosuppressive therapy, making a 
comparison with the present study difficult.   
Our study is limited because of the relatively small number of patients and the fact that it 
was not a randomized study. In addition, the fact that this study is the second to evaluate the 
prognostic significance of quantitatively determined IFTA implicates the need for a re-evaluation 
of our results (especially a low cut-off IFTA value for progression of renal disease) in future 
prospective studies. If quantitative IFTA measurement proves to be a more reliable marker of 
disease progression than semi-quantitative measurement, it would be easy to implement it. The 
tools used for quantifying IFTA are readily available (like ImageJ that we used), but in clinical 
practice, an automated high throughput system using whole-slide imaging would allow even a 
faster analysis, as well as the translation of the results of our study in the future.  
In conclusion, following the evaluation of several prospective prognostic factors of IMN 
progression, our study identified quantitatively measured IFTA as the most predictive one. If the 
present findings are confirmed, they could be easily translated into a routine method of biopsy 
analysis in IMN. 
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TABLES 
Table 1. Clinical data at baseline (values are given as mean±SD for normally distributed 
continuous variables and as median with interquartile range for nonparametric continuous 
variables) 
  
All patients (n=60) 
PRIMARY OUTCOME (RF
†
 or death)  
NO (n=48) YES (n=12) p 
Age (years) 52.4±13.8 51.31±14.13 56.67±11.67 NS 
Gender (female/male, %) 40/60 35.4/64.6 58.3/41.7 NS 
Hypertension (%) 73.3 70.8 83.3 NS 
Systolic blood pressure (mmHg) 151.07±29.04 148.52±28.18 161.25±31.42 NS 
Diastolic blood pressure (mmHg) 91.48±12.87 90.71±12.93 94.58±12.70 NS 
MAP
‡
 (mmHg) 111.12±16.53 109.67±16.18 116.95±17.35 NS 
Serum Creatinine (µmol/l) 104.97±52.33 97.58±43.91 134.50±72.55 0.043
* 
EGFR
§
 (ml/min) 75.28±28.54 79.94±26.76 56.65±28.93 0.010
* 
Serum Cholesterol (mmol/l) 8.25 (6.15-12.07) 8.13 (6.00-11.15)  11.67 (7.80-13.05) 0.021
** 
Serum Albumin (g/l) 25.15±8.30 26.44±8.12 19.98±7.17 0.015
* 
Maximal 24-hour proteinuria 
(g/1.73m
2
) 
7.74 (5.61-12.62) 7.15 (4,71-12.19)  12.90 (7.68-17.35)  0.008
** 
Immunosupressive therapy (%) 
yes / no 
85.0 / 15.0 85.4 / 14.6 83.3 / 16.7 NS 
*
 - Student t – test; 
**
 - Mann-Whitney U – test; 
†
RF=renal failure (>=50% permanent decrease in 
EGFR from baseline); 
‡
MAP=mean arterial pressure; 
§
EGFR=estimated glomerular filtration 
rate. 
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Table 2. Basic light, immunofluorescence and electron microscopy findings  
  
All patients (n=60) 
PRIMARY OUTCOME (RF
†
 or death)  
NO (n=48) YES (n=12) p 
Ehrenreich-Churg Stage (%) 
I / II / III / IV 
13.3/43.3/28.3/15.1 16.7/41.7/29.1/12.5 0.0/50.0/25.0/25.0 NS 
Ehrenreich-Churg Stage (%) 
I or II / III or IV 
56.6 / 43.4 58.3 / 41.7 50.0 / 50.0 NS 
Grade of IgG deposition (%) 
0 / 1 / 2 / 3 
1.7/23.3/38.3/36.7 0.0/27.1/35.4/37.5 8.4/8.3/50.0/33.3 NS 
Grade of C3 deposition (%) 
0 / 1 / 2 / 3 
11.7/51.7/25.0/11.7 12.5/54.2/25.0/8.3 8.3/41.7/25.0/25.0 NS 
Heterogenous immune deposits 
(%) 
51.7 47.9 66.7 NS 
Grade of nephroangiosclerosis (%) 
0 / 1 / 2 / 3 
45.0/31.7/15.0/8.3 50.0/35.4/10.4/4.2 25.0/16.7/33.3/25.0 0.013
* 
Secondary FSGS
§
 (%) 56.7 54.2 66.7 NS 
*
-χ
2
 – test; 
†
RF=renal failure (>=50% permanent decrease in EGFR from baseline); 
‡
MAP=mean 
arterial pressure; §FSGS=focal segmental glomerulosclerosis. 
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Table 3. Morphometric data at baseline (Continuous variables values are given as mean±SD for 
normally distributed variables and as median with interquartile range for non-normally 
distributed variables) 
  
All patients (n=60) 
PRIMARY OUTCOME  
(RF
†
 or death) 
 
NO (n=48) YES (n=12) p 
Glomerular area (GA, mm
2
) 0.040±0.009 0.039±0.008 0.041±0.012 NS 
Tuft area (TA, mm
2
) 0.032±0.007 0.032±0.007 0.033±0.010 NS 
Mesangial area (MA, mm
2
) 0.015±0.004 0.015±0.003 0.016±0.005 NS 
Urinary space area (UA, mm
2
) 0.008±0.003 0.008±0.002 0.009±0.003 NS 
Capillary space area (CA, mm
2
) 0.017±0.004 0.017±0.004 0.017±0.005 NS 
Glomerular diameter (GD, 
mm) 
0.231±0.029 0.229±0.027 0.237±0.038 NS 
Tuft diameter (TD, mm) 0.209±0.029 0.209±0.027 0.213±0.038 NS 
Tuft volume fraction  
(TVF, in %) 
80.093±4.518 80.440±4.264 78.706±5.400 NS 
Urinary space volume fraction  
(UVF, in %) 
19.907±4.518 19.560±4.264 21.294±5.400 NS 
Mesangial volume fraction  
(MVF, in %) 
37.576±4.270 37.524±4.472 37.783±3.506 NS 
Capillary space volume 
fraction (CVF, in %) 
42.517±5.310 42.916±5.301 40.923±5.264 
 
NS 
Glomerular basement 
membrane thickness  
(GBMT, nm) 
882.258±335.133 847.320±337.270 1016.187±303.272 0.049
* 
Glomerulopathy index (GPI) 125.858±34.424 122.325±35.344 139.402±27.891 0.027
* 
Interstitial fibrosis and tubular 
atrophy (IFTA, in %) 
10.0 (8.0-32.75) 10.00 (5.50-16.50) 
 
38.40 (30.00-55.00) 
 
<0.000
** 
Injury score (IS) 0.274 (0.165-0.514) 0.239 (0.141-0.374) 0.555 (0.339-0.922)  0.001
** 
*
 - Student t – test; 
**
 - Mann-Whitney U – test; 
†
RF=renal failure (>=50% permanent decrease in 
EGFR from baseline). 
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Table 4. Sensitivity, specificity, PPV
†
 and NPV
‡
 of the most discriminate threshold levels of 
significant clinical and morphometric parameters in the prediction of primary outcome (RF
§
 or 
death) 
Parameter AUC
¶ 
Threshold 
(cut-off) 
Sensitivity 
(%) 
Specificity 
(%) 
PPV NPV p 
Interstitial fibrosis and  
tubular atrophy (%) 
0.872 >18.0 91.67 77.08 50.0 97.4 <0.001 
Injury score (IS) 0.829 >0.322 91.67 75.0 47.8 97.3 <0.001 
Glomerulopathy index (GPI) 0.688 >124.154 75.0 63.04 34.6 90.6 0.046 
Maximal 24-hour proteinuria (g) 0.747 >7.2 83.33 54.17 31.3 92.9 0.012 
Estimated glomerular  
filtration rate (ml/min) 
0.729 ≤51.51 58.33 85.42 50.0 89.1 0.015 
Serum albumine (g/l) 0.719 ≤27.2 91.67 43.75 28.9 95.5 0.020 
Serum cholesterol (mmol/l) 0.716 >11.0 66.7 70.0 40.0 90.0 0.021 
Serum creatinine (µmol/l) 0.690 >102.0 58.33 81.25 43.8 88.6 0.043 
†
PPV= positive predictive value; 
‡
NPV=negative predictive value; 
§
RF=renal failure (>=50% 
permanent decrease in estimated glomerular filtration rate from baseline); 
¶
AUC=area under 
curve. 
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Table 5. The multivariate Cox proportional hazards model for the association of potentially 
predictive variables with primary outcome (RF
†
 or death) 
 Hazard ratio 95% CI
‡ 
p 
Serum Cholesterol (mmol/l) 1.015 0.719-1.433 0.932 
Serum Albumin (g/l) 0.886 0.771-1.019 0.090 
Estimated glomerular filtration rate (ml/minute) 0.974 0.943-1.005 0.103 
Maximal 24-hour proteinuria (g) 1.127 1.011-1.053 0.008 
Interstitial fibrosis and tubular atrophy (%) 1.029 1.007-1.051 0.010 
Injury score 0.123 0.002-6.944 0.308 
Glomerular basement membrane thickness (nm) 0.992 0.973-1.012 0.453 
Glomerulopathy index 1.062 0.876-1.288 0.537 
Nephroangiosclerosis grade (2 or 3 vs. 0 or 1) 1.972 0.337-11.554 0.451 
†
RF = >=50% permanent decrease in estimated glomerular filtration rate during follow-up; 
‡
CI=confidence interval. 
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FIGURES
 
Figure 1. Receiver operating characteristics (ROC) curves analysis for evaluating cut-off value 
of optimal interstitial fibrosis and tubular atrophy (IFTA) percentage to predict primary outcome 
(>=50% permanent decrease in estimated glomerular filtration rate during follow-up or death). 
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Figure 2. Receiver operating characteristics (ROC) curves analysis for evaluating cut-off value 
of optimal injury score (IS) to predict primary outcome (>=50% permanent decrease in estimated 
glomerular filtration rate during follow-up or death). 
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Figure 3. Renal and patient survival rate by Kaplan-Meier survival analysis and log-rank test of 
patients in the groups with interstitial fibrosis and tubular atrophy (IFTA) percentage >18% or 
<=18%. 
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Figure 4. Renal and patient survival rate by Kaplan-Meier survival analysis and log-rank test of 
patients in the groups with injury score (IS) >0.322 or <=0.322. 
